 "Dr Reddy's")
Shares of Dr Reddy’s Laboratories have gained 6.5% to Rs 2,559 on the BSE in intra-day trade so far after the company reported a good operational performance in September quarter (Q2FY19), on account of lower R&D, higher other income, financial income, and lower tax.
Earnings before interest, tax, depreciation and amortization (Ebitda) margin of the drug maker improved by 340 bps at 22.8% in Q2FY19 from 19.4% in Q2FY18. In Q1FY19, Ebitda stood at 19.4%.
“The year-on-year (Y-o-Y) improvement in gross margin primarily aided by contribution from new launches, improved leverage, better product mix coupled with favorable foreign
Earnings before interest, tax, depreciation and amortization (Ebitda) margin of the drug maker improved by 340 bps at 22.8% in Q2FY19 from 19.4% in Q2FY18. In Q1FY19, Ebitda stood at 19.4%.
“The year-on-year (Y-o-Y) improvement in gross margin primarily aided by contribution from new launches, improved leverage, better product mix coupled with favorable foreign
